keyword
https://read.qxmd.com/read/36463981/melatonin-and-metformin-counteract-cognitive-dysfunction-equally-in-male-rats-with-doxorubicin-induced-chemobrain
#21
JOURNAL ARTICLE
Titikorn Chunchai, Hiranya Pintana, Apiwan Arinno, Benjamin Ongnok, Patcharapong Pantiya, Thawatchai Khuanjing, Nanthip Prathumsap, Chayodom Maneechote, Nipon Chattipakorn, Siriporn C Chattipakorn
Melatonin (Mel) and metformin (Met) show beneficial effects in various brain pathologies. However, the effects of Mel and Met on doxorubicin (DOX)-induced chemobrain remain in need of elucidation. We aimed to investigate whether Mel and Met provide neuroprotective effects on glial dysmorphologies, brain inflammation, oxidative stress, brain mitochondrial dysfunction, apoptosis, necroptosis, neurogenesis, hippocampal dysplasticity, and cognitive dysfunction in rats with DOX-induced chemobrain. Thirty-two male Wistar rats were divided into 2 groups and received normal saline (NSS, as control, n = 8) or DOX (3 mg/kg/day; n = 24) by intraperitoneal (i...
January 2023: Neurotoxicology
https://read.qxmd.com/read/36455340/synergistic-effect-of-metformin-and-doxorubicin-on-the-metastatic-potential-of-t24-cells
#22
JOURNAL ARTICLE
Agnieszka Mlicka, Paweł Mlicki, Paweł Niewiadomski, Wioletta Zielińska, Marta Hałas-Wiśniewska, Magdalena Izdebska
BACKGROUND: The motor ability of cancer cells to cross the basement membrane contributes to their implantation in a new location. Metastasis is a significant factor that worsens the prognosis of cancer patients. Thus, reducing cell invasiveness is an important aspect of anticancer therapy, also in bladder cancer treatment. MATERIAL: The study material was the T24 cell line of human urinary bladder cancer. The migratory potential of the cells and the effect of the treatment with individually doses and synergistic combination of doxorubicin and metformin in the 500:1 ratio for 24 h were analyzed...
January 2023: Acta Histochemica
https://read.qxmd.com/read/36403763/layer-by-layer-development-of-chitosan-alginate-based-platelet-mimicking-nanocapsules-for-augmenting-doxorubicin-cytotoxicity-against-breast-cancer
#23
JOURNAL ARTICLE
Alaa Ibrahim, Islam A Khalil, Mohamed Y Mahmoud, Alaa F Bakr, Monira G Ghoniem, Eida S Al-Farraj, Ibrahim M El-Sherbiny
Breast carcinoma is considered one of the most invasive and life-threatening malignancies in females. Mastectomy, radiation therapy, hormone therapy and chemotherapy are the most common treatment choices for breast cancer. Doxorubicin (DOX) is one of the most regularly utilized medications in breast cancer protocols. However, DOX has showed numerous side effects including lethal cardiotoxicity. This study aims to fortify DOX cytotoxicity and lowering its side effects via its combining with the antidiabetic metformin (MET) as an adjuvant therapy, along with its effective delivery using natural platelet-rich plasma (PRP), and newly-developed PRP-mimicking nanocapsules (NCs)...
November 17, 2022: International Journal of Biological Macromolecules
https://read.qxmd.com/read/36015440/the-synergistic-effects-of-curcumin-and-chemotherapeutic-drugs-in-inhibiting-metastatic-invasive-and-proliferative-pathways
#24
REVIEW
Maria Younes, Rita Mardirossian, Liza Rizk, Tia Fazlian, Jean Paul Khairallah, Christopher Sleiman, Hassan Y Naim, Sandra Rizk
Curcumin, the main phytochemical identified from the Curcuma longa L. family, is one of the spices used in alternative medicine worldwide. It has exhibited a broad range of pharmacological activities as well as promising effects in the treatment of multiple cancer types. Moreover, it has enhanced the activity of other chemotherapeutic drugs and radiotherapy by promoting synergistic effects in the regulation of various cancerous pathways. Despite all the literature addressing the molecular mechanism of curcumin on various cancers, no review has specifically addressed the molecular mechanism underlying the effect of curcumin in combination with therapeutic drugs on cancer metastasis...
August 17, 2022: Plants (Basel, Switzerland)
https://read.qxmd.com/read/35989018/chitosan-biguanide-induced-mitochondrial-inhibition-to-amplify-the-efficacy-of-oxygen-sensitive-tumor-therapies
#25
JOURNAL ARTICLE
Zaigang Zhou, Chunjuan Zheng, Yu Liu, Wenjuan Luo, Hui Deng, Jianliang Shen
At present, the tumor's poor oxygen perfusion and limited tumor drug permeation are the major bottlenecks that limit the therapeutic effectiveness of the oxygen-sensitive antitumor therapies, like doxorubicin (Dox)-mediated chemotherapy and photodynamic therapy (PDT). To our best knowledge, the abnormal tumor mitochondria oxidative phosphorylation (OXPHOS) was the vital cause of such phenomenon, which induced the hypoxia tumor microenvironment and enhanced drug efflux from tumor cells via enhanced multidrug resistance protein 1 (MDR-1) expression...
November 1, 2022: Carbohydrate Polymers
https://read.qxmd.com/read/35912098/identification-of-an-m6a-related-long-noncoding-rna-risk-model-for-predicting-prognosis-and-directing-treatments-in-patients-with-colon-adenocarcinoma
#26
JOURNAL ARTICLE
Wanying Liao, Junyu Long, Yiran Li, Fucun Xie, Ziyu Xun, Yanyu Wang, Xu Yang, Yunchao Wang, Kang Zhou, Xinting Sang, Haitao Zhao
N6-methyladenosine (m6A) and lncRNAs have been implicated in the development of colon cancer, including tumorigenesis, migration, and invasion. However, the specific effect of m6A regulators on lncRNAs is not clear, and m6A-related lncRNAs may be new prognostic biomarkers and may help direct treatment and medication. We identified 29 prognostic m6A-related lncRNAs and constructed a risk model using 12 lncRNAs. The model was an independent prognostic factor and could accurately predict the prognosis. A stable and robust nomogram that combined the model and pathologic stage was constructed...
2022: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/35750278/reversing-multi-drug-resistance-by-polymeric-metformin-to-enhance-antitumor-efficacy-of-chemotherapy
#27
JOURNAL ARTICLE
Hongyan Zhang, Jiandong Yu, Lisha Ma, Yue Zhao, Shujun Xu, Jingbin Shi, Ke Qian, Mancang Gu, Hongsheng Tan, Li Xu, Yun Liu, Chaofeng Mu, Yang Xiong
Multi-drug resistance (MDR) in breast cancer poses a great threat to chemotherapy. The expression and function of the ATP binding cassette (ABC) transporter are the major cause of MDR. Herein, a linear polyethylene glycol (PEI) conjugated with dicyandiamide, which called polymeric metformin (PolyMet), was successfully synthesized as a simple and biocompatible polymer of metformin. PolyMet showed the potential to reverse MDR by inhibiting the efflux of the substrate of ATP-binding cassette (ABC) transporter from DOX resistant MCF-7 cells (MCF-7/DOX)...
August 25, 2022: International Journal of Pharmaceutics
https://read.qxmd.com/read/35613685/development-and-evaluation-of-core-shell-nanocarrier-system-for-enhancing-the-cytotoxicity-of-doxorubicin-metformin-combination-against-breast-cancer-cell-line
#28
JOURNAL ARTICLE
Alaa Ibrahim, Islam A Khalil, Ibrahim M El-Sherbiny
Breast cancer is the most invasive and life-threatening cancer in women. The treatment options are usually a combination of mastectomy, radiation therapy, hormonal therapy and chemotherapy. As a standard practice, doxorubicin (DOX) is one of the commonly used drugs for breast cancer treatment. However, DOX is known to have many harmful adverse effects including its cardiotoxicity. Hence, recent reports used metformin (MET), an anti-diabetic drug, as an adjuvant therapy to decrease the severity of DOX's adverse effects and to improve its ultimate therapeutic outcome...
May 22, 2022: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/35398171/characterization-of-cellular-senescence-in-doxorubicin-induced-aging-mice
#29
JOURNAL ARTICLE
Tianyue Sun, Lanxin Zhang, Jiali Feng, Lingyuan Bao, Jiqun Wang, Zhouzhi Song, Zhifan Mao, Jian Li, Zelan Hu
With a rise in the need to develop anti-aging drugs, a growing number of in vivo studies evaluating the efficacy of potential drug candidates have used doxorubicin-induced aging mice. However, changes in the biomarkers of senescent cells have not been reported in detail in these animals. To lay a foundation for the use of doxorubicin-induced aging mice, we examined the biomarkers of hepatic and renal senescent cells in these mice. We found that the 5 mg/kg doxorubicin dose is optimal to induce cellular senescence in mice...
June 15, 2022: Experimental Gerontology
https://read.qxmd.com/read/35141304/demystifying-the-relationship-between-metformin-ampk-and-doxorubicin-cardiotoxicity
#30
REVIEW
Manrose Singh, Akito T Nicol, Jaclyn DelPozzo, Jia Wei, Mandeep Singh, Tony Nguyen, Satoru Kobayashi, Qiangrong Liang
Doxorubicin (DOX) is an extremely effective and wide-spectrum anticancer drug, but its long-term use can lead to heart failure, which presents a serious problem to millions of cancer survivors who have been treated with DOX. Thus, identifying agents that can reduce DOX cardiotoxicity and concurrently enhance its antitumor efficacy would be of great clinical value. In this respect, the classical antidiabetic drug metformin (MET) has stood out, appearing to have both antitumor and cardioprotective properties...
2022: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/35109026/melatonin-metformin-and-ranolazine-equally-improved-cognitive-function-in-rats-with-doxorubicin-induced-chemobrain
#31
JOURNAL ARTICLE
Titikorn Chunchai, Benjamin Ongnok, Patcharapong Pantiya, Apiwan Arinno, Thawatchai Khuanjing, Nanthip Prathumsap, Chayadom Maneechote, Sasiwan Kerdphoo, Thidarat Jaiwongkam, Nipon Chattipakorn, Siriporn C Chattipakorn
BACKGROUND: Doxorubicin (Dox), the common therapeutic regimen for breast cancer treatment, has been shown the toxicity to the brain, known as "chemotherapy-induced cognitive impairment or chemobrain". However, the mechanisms of doxorubicin-induced chemobrain are not fully understood. Melatonin, metformin, and ranolazine have been shown the neuroprotective effects on mitochondrial function and cognition in several pathological conditions. However, the effects of melatonin, metformin, and ranolazine on peripheral oxidative stress, brain mitochondrial function, synaptic plasticity, and cognitive function in Dox-induced chemobrain has never been investigated...
December 2021: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/34989923/automated-assessment-of-cancer-drug-efficacy-on-breast-tumor-spheroids-in-aggrewell%C3%A2-400-plates-using-image-cytometry
#32
JOURNAL ARTICLE
Shilpaa Mukundan, Jordan Bell, Matthew Teryek, Charles Hernandez, Andrea C Love, Biju Parekkadan, Leo Li-Ying Chan
Tumor spheroid models have proven useful in the study of cancer cell responses to chemotherapeutic compounds by more closely mimicking the 3-dimensional nature of tumors in situ. Their advantages are often offset, however, by protocols that are long, complicated, and expensive. Efforts continue for the development of high-throughput assays that combine the advantages of 3D models with the convenience and simplicity of traditional 2D monolayer methods. Herein, we describe the development of a breast cancer spheroid image cytometry assay using T47D cells in Aggrewell™400 spheroid plates...
March 2022: Journal of Fluorescence
https://read.qxmd.com/read/34924899/synergistic-effects-of-metformin-and-curcumin-on-cytotoxicity-of-chemotherapy-drugs-using-a-gastric-cancer-cell-line-model
#33
JOURNAL ARTICLE
Ehsan Zarei, Youssof Sefidi-Heris, Iraj Saadat
Gastric cancer has a weak prognosis and its usual treatments depend on surgery and chemotherapy. These treatments suffer from some drawbacks such as high rates of local recurrence and metastasis, low survival rates, and significantly decreased life quality. Therefore, new therapeutic methods for improved gastric cancer care with minimal side effects seem necessary. Currently, combinatorial treatments for cancer are preferred and recently, metformin (Met) and curcumin (Cur) have been interesting options for this type of therapy...
2021: EXCLI Journal
https://read.qxmd.com/read/34881354/protective-effect-of-aqueous-leaf-extracts-of-chromolaena-odorata-and-tridax-procumbens-on-doxorubicin-induced-hepatotoxicity-in-wistar-rats
#34
JOURNAL ARTICLE
Catherine C Ikewuchi, Jude C Ikewuchi, Mercy O Ifeanacho, Damiete P Jack, Caleb N Ikpe, Samuel Ehiosun, Tosin B Ajayi
BACKGROUND: The liver is one of the organs affected by doxorubicin toxicity. Therefore, in this study, the potential protective role of aqueous leaf extracts of Chromolaena odorata and Tridax procumbens against doxorubicin-induced hepatotoxicity was investigated. METHODS: In order to achieve this, their impact on hepatic biomarkers of oxidative stress, lipid and electrolytes' profile, and plasma biomarkers of liver functions/integrity were monitored in doxorubicin treated rats...
November 2021: Porto Biomedical Journal
https://read.qxmd.com/read/34611148/ganitumab-and-metformin-plus-standard-neoadjuvant-therapy-in-stage-2-3-breast-cancer
#35
JOURNAL ARTICLE
Douglas Yee, Claudine Isaacs, Denise M Wolf, Christina Yau, Paul Haluska, Karthik V Giridhar, Andres Forero-Torres, A Jo Chien, Anne M Wallace, Lajos Pusztai, Kathy S Albain, Erin D Ellis, Heather Beckwith, Barbara B Haley, Anthony D Elias, Judy C Boughey, Kathleen Kemmer, Rachel L Yung, Paula R Pohlmann, Debu Tripathy, Amy S Clark, Hyo S Han, Rita Nanda, Qamar J Khan, Kristen K Edmiston, Emanuel F Petricoin, Erica Stringer-Reasor, Carla I Falkson, Melanie Majure, Rita A Mukhtar, Teresa L Helsten, Stacy L Moulder, Patricia A Robinson, Julia D Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M Asare, Amy Wilson, Gillian L Hirst, Ruby Singhrao, Adam L Asare, Jeffrey B Matthews, Nola M Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S Rugo, W Fraser Symmans, Laura J Van't Veer, Donald A Berry, Laura J Esserman
I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal antibody designed to bind and inhibit function of the type I insulin-like growth factor receptor (IGF-1R). Ganitumab was tested in combination with metformin and paclitaxel (PGM) followed by AC compared to standard-of-care alone. While pathologic complete response (pCR) rates were numerically higher in the PGM treatment arm for hormone receptor-negative, HER2-negative breast cancer (32% versus 21%), this small increase did not meet I-SPY's prespecified threshold for graduation...
October 5, 2021: NPJ Breast Cancer
https://read.qxmd.com/read/34609385/a-metformin-based-nanoreactor-alleviates-hypoxia-and-reduces-atp-for-cancer-synergistic-therapy
#36
JOURNAL ARTICLE
Xiangyu Meng, Jia Song, Yunfeng Lei, Xuezhong Zhang, Zhixin Chen, Zhuoxuan Lu, Liming Zhang, Zhifei Wang
Severe hypoxia in solid tumors limits the efficacy of oxygen (O2 )-dependent photodynamic therapy (PDT). The overexpressed heat shock proteins (HSPs) in tumor cells hamper the effect of photothermal therapy (PTT). Herein, a tumor oxygenation-enhanced and ATP-reduced gelatin nanoreactor (MCGPD ∼ RGD NPs) for PDT/PTT-augmented combination cancer therapy is reported. In this nanosystem, the Arg-Gly-Asp (RGD) peptides of MCGPD ∼ RGD NPs can ensure accurate recognition and sufficient accumulation in the tumor site...
November 9, 2021: Biomaterials Science
https://read.qxmd.com/read/34536497/in-vitro-and-in-vivo-investigation-of-amygdalin-metformin-and-combination-of-both-against-doxorubicin-on-hepatocellular-carcinoma
#37
JOURNAL ARTICLE
Ahmed M Mamdouh, Dina M Khodeer, Mohamed A Tantawy, Yasser M Moustafa
AIM: Hepatocellular carcinoma (HCC) is a potentially life-threatening cancer. In the current study, anti-HCC efficacy of amygdalin, or metformin alone or in combination in comparison to doxorubicin was studied. MAIN METHODS: Both in-vitro and in-vivo based models. HepG-2 and Huh-7 cell lines as established in-vitro model for HCC were treated with different concentrations of indicated drugs to evaluate the cytotoxicity and determine IC50 for 24, 48 and 72 h. Moreover, the effect of different treatments on apoptosis and cell cycle using flow cytometric analysis were studied...
November 15, 2021: Life Sciences
https://read.qxmd.com/read/34502073/exercise-but-not-metformin-prevents-loss-of-muscle-function-due-to-doxorubicin-in-mice-using-an-in-situ-method
#38
JOURNAL ARTICLE
Amy D Mackay, Erik D Marchant, Makensie Louw, David M Thomson, Chad R Hancock
Though effective in treating various types of cancer, the chemotherapeutic doxorubicin (DOX) is associated with skeletal muscle wasting and fatigue. The purpose of this study was to assess muscle function in situ following DOX administration in mice. Furthermore, pre-treatments with exercise (EX) or metformin (MET) were used in an attempt to preserve muscle function following DOX. Mice were assigned to the following groups: control, DOX, DOX + EX, or DOX + MET, and were given a single injection of DOX (15 mg/kg) or saline 3 days prior to sacrifice...
August 25, 2021: International Journal of Molecular Sciences
https://read.qxmd.com/read/34453902/cardioprotective-effects-of-melatonin-and-metformin-against-doxorubicin-induced-cardiotoxicity-in-rats-are-through-preserving-mitochondrial-function-and-dynamics
#39
JOURNAL ARTICLE
Apiwan Arinno, Chayodom Maneechote, Thawatchai Khuanjing, Benjamin Ongnok, Nanthip Prathumsap, Titikorn Chunchai, Busarin Arunsak, Sasiwan Kerdphoo, Krekwit Shinlapawittayatorn, Siriporn C Chattipakorn, Nipon Chattipakorn
Doxorubicin (Dox) is widely used in chemotherapy regimens for several malignant conditions. Unfortunately, cumulative and irreversible cardiotoxicity of Dox is the most prominent adverse effect which limits its use. Several pharmacological interventions which exert antioxidant properties, including melatonin and metformin, have demonstrated beneficial effects against various cardiac pathological conditions. However, the exact molecular mechanisms underlying their cardioprotective effects are not completely understood...
October 2021: Biochemical Pharmacology
https://read.qxmd.com/read/34336442/mechanisms-and-potential-treatment-options-of-heart-failure-in-patients-with-multiple-myeloma
#40
REVIEW
Ekaterina Proskuriakova, Keji Jada, Sandrine Kakieu Djossi, Anwar Khedr, Bandana Neupane, Jihan A Mostafa
Multiple myeloma is a pathology of plasma cells, with one of the most common side effects of its treatment is heart failure. In addition, cardiac amyloidosis could cause heart failure by itself. Even though mechanisms of cardiac amyloidosis are known, and they involve lysosomal dysfunction, reactive oxygen species (ROS) accumulation, and infiltrative effect by fibrils, there is no specific agent that could protect from these effects. While the molecular mechanism of doxorubicin cardiotoxicity via topoisomerase II β is established, the only FDA-approved agent for treatment is dexrazoxane...
June 2021: Curēus
keyword
keyword
158876
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.